BRAF and neoplasm: Overall, 25.13% (92 of 366) of BRAF V600E positive patients and 17.55% (56 of 319) of BRAF V600E negative patients experienced recurrence with an unadjusted OR of 1.65 (95% CI, 1.13 to 2.42) (p 0.009), which remained significant after adjustment for patient age and sex (OR, 1.73; 95% CI, 1.19 to 2.56)(p 0.005) yet it did not remain significant after additional adjustment for tumor size, extrathyroidal invasion, lymph node metastasis, multifocality and RAI (OR, 1.57; 95% CI, 0.95-2.62) (p=0.078).